Printer Friendly

QMED, INC. RECEIVES PATENT

 LAURENCE HARBOR, N.J., Sept. 29 /PRNewswire/ -- qmed, Inc. (NASDAQ: QEKG), reported today that the company had received a patent notice of allowance (Patent No. 7,626,710) for its nDx device. Michael Cox, president of qmed, said that the patent covers "autonomic neuropathy detection and a method of analysis." The patented nDx system automates the diagnostic test methods that were used in the landmark Diabetes Control and Complications Trial (DCCT) for the detection of autonomic neuropathy. The DCCT was supported by grants from the National Institutes of Health and others. The DCCT results published in the Sept. 30 issue of the New England Journal of Medicine demonstrate a greater than 60 percent reduction in nerve damage when combining such diagnostic testing with tight glucose control.
 Cox concluded that the issuance of the patent secures broad protection for its automated method of analysis of diabetic autonomic neuropathy. This patented method of analysis provides primary ?physicians and specialists with a simple, non-invasive procedure to detect and manage diabetic autonomic neuropathy in a non-hospital setting.
 qmed, Inc. manufactures a wide array of medical diagnostic products which are designed for primary care physicians.
 -0- 9/29/93
 /CONTACT: Denise Queffelec, vice president-product development of qmed, 800-237-2039/
 (QEKG)


CO: qmed, Inc. ST: New Jersey IN: MTC SU:

SH-TS -- NY050 -- 6881 09/29/93 14:13 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1993
Words:222
Previous Article:HANDY & HARMAN CEO SPEAKS AT THE CHICAGO STOCK EXCHANGE CLUB
Next Article:WILEY ACQUIRES BELHAVEN PRESS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters